Cue Biopharma, Inc. (CUE) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CUE Revenue Growth
CUE Revenue Analysis (2015–2025)
As of May 8, 2026, Cue Biopharma, Inc. (CUE) generated trailing twelve-month (TTM) revenue of $27.5 million, reflecting explosive growth of +1292.3% year-over-year. The most recent quarter (Q4 2025) recorded $21.9 million in revenue, up 921.0% sequentially.
Looking at the longer-term picture, CUE's 5-year compound annual growth rate (CAGR) stands at +54.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $27.5 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including AGIO (+78.3% YoY), KYMR (-12.6% YoY), and RCUS (+67.4% YoY), CUE has outperformed the peer group in terms of revenue growth. Compare CUE vs AGIO →
CUE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CUECurrent | $27M | +1292.3% | +54.2% | -96.7% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
CUE Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $27.5M | +195.7% | $24.0M | 87.3% | $-26,552,000 | -96.7% |
| 2024 | $9.3M | +69.2% | $9.3M | 100.0% | $-41,500,000 | -446.9% |
| 2023 | $5.5M | +341.0% | $-32,607,000 | -593.9% | $-52,149,000 | -949.9% |
| 2022 | $1.2M | -91.7% | $1.2M | 100.0% | $-53,225,000 | -4275.1% |
| 2021 | $14.9M | +373.7% | $16.7M | 111.9% | $-43,712,073 | -292.6% |
| 2020 | $3.2M | -8.8% | $-30,391,379 | -963.5% | $-45,042,585 | -1428.0% |
| 2019 | $3.5M | +202.7% | $-24,029,154 | -694.8% | $-36,769,247 | -1063.2% |
| 2018 | $1.1M | - | $-27,401,447 | -2398.2% | $-38,696,658 | -3386.7% |
| 2017 | $0 | - | $-419,568 | - | $-23,233,870 | - |
| 2016 | $0 | - | $-202,085 | - | $-7,658,335 | - |
See CUE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CUE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CUE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCUE — Frequently Asked Questions
Quick answers to the most common questions about buying CUE stock.
Is CUE's revenue growth accelerating or slowing?
CUE revenue is accelerating at +1292.3% year-over-year, exceeding the 5-year CAGR of +54.2%. TTM revenue reached $27M. Growth momentum has increased versus prior periods.
What is CUE's long-term revenue growth rate?
Cue Biopharma, Inc.'s 5-year revenue CAGR of +54.2% reflects the sustained expansion pattern. Current YoY growth of +1292.3% is above this long-term average.
How is CUE's revenue distributed by segment?
CUE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.